{
  "id": "fda_guidance_chunk_0725",
  "title": "Introduction - Part 725",
  "text": "CONTROL (SEE SECTION 1.3.3) (2.3) ............................................................ 21 1. Description (2.3.1)......................................................................................................................................... 21 2. Ability to Minimize Bias (2.3.2) .................................................................................................................... 22 3. Ethical Issues (2.3.3)...................................................................................................................................... 22 4. Usefulness of Dose-response Studies and Validity of Inference in Particular Situations (2.3.4)............. 22 5. Modifications of Design and Combinations with Other Controls That Can Resolve Ethical, Practical, or Inferential Problems (2.3.5) .................................................................................................................................... 22 ii 6. Advantages of Dose-response Trials (2.3.6) ................................................................................................ 22 a. Efficiency (2.3.6.1) ............................................................................................................................................. 22 b. Possible Ethical Advantage (2.3.6.2) ................................................................................................................... 23 7. Disadvantages of Dose-response Study (2.3.7)............................................................................................ 23 D. ACTIVE CONTROL (SEE SECTION 1.3.4) (2.4) .................................................................................................... 23 1. Description (2.4.1)......................................................................................................................................... 23 2. Ability to Minimize Bias (2.4.2) .................................................................................................................... 24 3. Ethical Issues (2.4.3)...................................................................................................................................... 24 4. Usefulness of Active Control Trials; Validity of Inference in Particular Situations (2.4.4)..................... 24 5. Modifications of Design and Combinations with Other Controls That Can Resolve Ethical, Practical, or Inferential Issues (2.4.5).......................................................................................................................................... 25 6. Advantages of Active Control Trials (2.4.6)................................................................................................. 25 a. Ethical and Practical Advantages (2.4.6.1) ........................................................................................................... 25 b. Information Content (2.4.6.2) .............................................................................................................................. 25 7. Disadvantages of Active Control Trials (2.4.7) ........................................................................................... 25 a. Information Content (2.4.7.1) .............................................................................................................................. 25 b. Large Sample Size (2.4.7.2) ................................................................................................................................ 25 E. EXTERNAL CONTROL (INCLUDING HISTORICAL CONTROL, SEE SECTION 1.3.5) (2.5).................................... 26 1. Description (2.5.1)......................................................................................................................................... 26 2. Ability to Minimize Bias (2.5.2) .................................................................................................................... 26 3. Ethical Issues (2.5.3)...................................................................................................................................... 27 4. Usefulness of Externally Controlled Trials; Validity of Inference in Particular Situations (2.5.4)......... 28 5. Modifications of Design and Combinations with Other Controls That Can Resolve Ethical, Practical or Inferential Problems (2.5.5) .................................................................................................................................... 28 6. Advantages of Externally Controlled Trials (2.5.6)..................................................................................... 29 7. Disadvantages of Externally Controlled Trials (2.5.7) ............................................................................... 29 III. CHOOSING THE CONCURRENT CONTROL GROUP (3.0) .................................................................... 29 Guidance for Industry1 E10 Choice of Control Group and Related Issues in Clinical Trials This guidance is intended to assist applicants in choosing a control group for clinical trials intended to demonstrate the efficacy of a treatment. The guidance also discusses related trial design and conduct issues and describes what trials using each design can demonstrate. This guidance does not address the regulatory requirements of any region. I. INTRODUCTION (1.0)2 The choice of control group is always a critical decision in designing a clinical trial. That choice affects the inferences that can be drawn from the trial, the ethical acceptability of the trial, the degree to which",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 973056,
  "end_pos": 974592,
  "tokens": 512,
  "tags": [
    "efficacy",
    "design",
    "statistical",
    "regulatory",
    "clinical_trial"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "mandatory",
  "created_at": "2025-10-23T02:25:44.734Z"
}